Skip to main content
SpringerLink
Log in

Elderly patients with acute myocardial infarction benefit from early treatment but drug choice is dependent on clinical presentation

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aronow WS. Drug treatment of elderly patients with acute myocardial infarction: practical recommendations. Drugs Aging 2001;18 (11): 807–18

    Article  PubMed  CAS  Google Scholar 

  2. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 1993; 23: 1273–7

    Article  Google Scholar 

  3. Elder AT, Fox KAA. Ischaemic heart disease in the elderly. Martin A, Camm AJ, editors. Geriatric cardiology principles and practice. Chichester: John Wiley and Sons Ltd. 1994: 333–70

    Google Scholar 

  4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016–30

    Article  PubMed  CAS  Google Scholar 

  5. British National Formulary. No. 43. London: The Pharmaceutical Press, 2002 Mar

  6. Hjalmarson A, Herbiz J, Malek J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; II: 823–7

    Article  Google Scholar 

  7. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomised, placebo-controlled international trial. Eur Heart J 1985; 6: 199–226

    Google Scholar 

  8. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986; II: 57–66

    Google Scholar 

  9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60

    Google Scholar 

  10. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 1995; 92: 2841–7

    Article  PubMed  CAS  Google Scholar 

  11. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  13. Kober L, Torp-Pederson C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6

    Article  PubMed  CAS  Google Scholar 

  14. Berger AK, Radford MJ, Wang Y, et al. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000; 36: 366–74

    Article  PubMed  CAS  Google Scholar 

  15. Fibrinolytic Therapy Trialist’s (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311–22

    Google Scholar 

  16. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720–32

    Article  PubMed  CAS  Google Scholar 

  17. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptors with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97

    Article  Google Scholar 

  18. The PURSUIT Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–43

    Article  Google Scholar 

  19. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Am J Coll Cardiol 1996; 27: 337–44

    Google Scholar 

  20. Soumerai SB, McLaughlin TJ, Spiegelman, D et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 227:115–21

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elderly patients with acute myocardial infarction benefit from early treatment but drug choice is dependent on clinical presentation. Drugs Ther. Perspect 19, 18–20 (2003). https://doi.org/10.2165/00042310-200319040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319040-00006

Keywords

Search

Navigation